Jianxiang Wang, Dr.
Institute of Hematology & Blood Diseases Hospital, China
7
7
3
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+7 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (7)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Aibin Liang, Dr.
Tongji Hospital
Shared therapeutic areas:
Worked with same sponsors:
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Elias Jabbour, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
xiaowen tang, Ph.D
The First Affiliated Hospital of Soochow University
Shared therapeutic areas:
Beata Holkova, MD
Massey Cancer Center
Shared therapeutic areas:
Brigitte C Widemann, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Partow Kebriaei, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Ryotaro Nakamura
City of Hope Medical Center
Shared therapeutic areas:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Qifa Liu
Nanfang Hospital, Southern Medical University
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (7)
Showing 7 of 7 trials
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
All 7 trials loaded